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Abstract: Patients with limited English proficiency living in the U.K. receive prescribed medication
labels in English. These patients are at risk of worse health outcomes compared with the general
population. This article describes a service evaluation of the use of bilingual dispensing labels to
facilitate patient understanding of medicine administration instructions. Recruited patients answered
two questionnaires to assess engagement with and understanding of their medicine labels. The first
was completed at the point of dispensing, and the second within six weeks. Questionnaires were
either self-completed or via facilitation over the telephone. A total of 151 participants completed the
first questionnaire, and 130 completed the follow-up. Key findings highlighted the lack of engagement
by participants with English-language labels and their reliance on asking for help from pharmacy
staff, friends, or family to understand the information. However, when provided with information in
their preferred language, they reported high levels of understanding and sought help less frequently
from a third party. This study has shown that this service has improved understanding of labelling
information in this target group.
Keywords: health literacy; language proficiency; bilingual labels; community pharmacy; medicine
related adherence; service implementation
1. Introduction
Medication non-adherence remains a major obstacle to the effective delivery of healthcare
globally [1], and is reported to account for 33% of all preventable drug-related hospital admissions [2].
While reasons that lead to non-adherence with prescribed medication are complex, the inability to
communicate has been identified as a key aspect preventing patients from taking their medicines
appropriately [3]. Misunderstanding administration instructions and confusing different medicines
have been found to be contributing factors [1]. Improving access to adequate administration
information can have an impact on medication adherence [4], preventing medication safety incidents,
including medicines-related hospital admissions, and reducing associated costs [2,5,6].
These issues are compounded in those patients living in an English-speaking country who are not
native English speakers. It is estimated that over one million people in the U.K. [7,8] and 26 million in
the U.S. [9] have limited English proficiency. The literature shows that health inequalities and poorer
outcomes affect this sector of the population particularly [7,10–12].
Despite the significance of these issues, little is known about how communication takes place with
patients with limited English [10,13]. Reported work has included the use of patient information leaflets,
interpreters and telephone interpreting services [14–18], with the latter two services often provided
by unqualified bilingual staff [14,16]. Additionally, there has been work, although limited, on the
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readability and understandability of bilingual medication labels, with findings suggesting that such
labels have an application to practice, through improving participants’ understanding [18–20]. Previous
literature has highlighted how barriers in understanding information would still be experienced by
patients supported by the provision of translated information leaflets [14,15]. Issues with the accessibility
of interpreters have also been reported, alongside concerns regarding the reliability of translations
when these were not qualified [13,21]. Also, while previous work looking at bilingual medication
labels have been undertaken, this has been sparse, looking at simplified, non-standardized medication
instructions [18], and labels including pictorial representations [19,20], with no previous studies aiming
to explore the perceived impact of standard dispensing labels with bilingual information.
The study reported in this paper was a service evaluation aimed to add to this work by establishing
patient acceptability when providing prescribed medication with bilingual dispensing labels to those
who do not speak English as their first language.
2. Materials and Methods
The service was offered through 12 community pharmacies in London who volunteered to
participate after expressions of interest were sought via a local professional pharmacy organization
independent from the research team. This organization was approached to invite expressions of
interest, as it represented pharmacies in an area that served a large proportion of patients with
limited English proficiency. Once the participating pharmacies had been identified, the research team
provided training and support to implement the service, which was provided independently under
the supervision of registered pharmacists in each of the settings with no affiliation to the research team.
The research study was therefore designed by the research team. Dispensing labels were produced
that contained both English and the translated language; specifically, the directions of use and any
associated warnings (Figure 1). These labels were produced using a cloud-based software similar to
the regular dispensing system, which is available throughout the U.K. and in use beyond the settings
where the service evaluation took place. The bilingual dispensing labels were not offered in the
12 participating pharmacies prior to them taking part in this work.
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Figure 1. Examples of bilingual dispensing labels.
The languages for which the service was available were Arabic, Bengali, Gujarati, Hindi, Polish,
Punjabi (Gurmukhi), Somali, and Tamil, and reflected the ethnic groupings that the pharmacies served.
Whilst no specific validation of the non-English labels was conducted, the translation software utilized
had undergone a four-tier quality assurance process through professional translators, and consisted
of: translation; proofreading; quality checking; and testing (by a qualified bilingual U.K. pharmacist).
In addition, the U.K. regulator, the General Pharmaceutical Council, was consulted, and confirmed
in an oral communication that these labels could be used, and referred the authors to several legal
documents pertaining to the labelling of medicines in the U.K., which state that English must be used,
but an additional language can be ad ed provided the same information is presented in the additional
languages [22–25]. Figure 2 highli hts the recruitment process.
The service was promoted through i isplays in the pharmacies and informed
participants to ask staff for details of the service. ecruitment was therefore predomi antly
participant-driven, althou tients known to staff whose first l nguage was not English were
made aware of the service and recruited opportunistically.
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Figure 2. Study protocol and recruitment.
Study exclusion were those patients who requested the service but whose preferred language
could not be translated by the software, or those who said they could not read their preferred
language. Consent to take part in the study was obtained from participants after provision of written
information about the project in the person’s preferred language and giving them the opportunity
to ask questions about the work to bilingual pharmacy staff. Consent forms were signed by the
individuals who agreed to do so prior to participation. These consent forms were also written in the
person’s preferred language.
Data Collection and Analysis
Data were collected from February 2016 to March 2017 from those participants who provided
consent to tak part in the study as described in Section 2. Patient data were gathered through the
mpletion of two ques ionnaires, available in the upplementary Materials: a baselin questionnair
at the pharmacy when they collected their dispensed medication and before they rece v d the bilingual
labels for the first tim , and a second follow-up qu stionnaire four to six weeks after. This tim fram
was chosen to allow for use of the medicines while aligning follow up with the pot ntial return of
patients for repeated medication a month lat r. A m istration of the questi nnaires were performed
by a ominat d taff memb r (pharmacist or pharmacy support st ff) who spoke the participant’s
re e red language.
The fir t questionn ire coll cted demographic data and questions about their understanding of
Englis labelling inf rm tion. Additionally, the pharmacist recorded whether medication was f r
a acute or chronic condi i an whether the supply wa n w or ongoing.
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The second questionnaire was completed either in the pharmacy on a subsequent return visit by
the participant or by contacting them via telephone. Participants were made aware on completion of
the first questionnaire that they may be contacted in this way.
All questions on both questionnaires were constructed to be simple closed–type questions to
facilitate understanding and completion rates.
For both questionnaires, descriptive statistics were used to summarize the data. An enquiry
to NHS National Research Ethics Service (NRES) was responded to by confirming that the study
was considered a service evaluation and did not require ethical review by an NHS Research Ethics
Committee (NRES Queries Line Ref. 04/31). Research ethics approval from the Science Faculty
Research Ethics committee at the University of Portsmouth was granted (reference number SFEC
2015—100) prior to commencing this work.
3. Results
3.1. Initial Questionnaire Data
A total of 151 participants completed the first questionnaire. Data on those who declined to
participate were not recorded. Demographic data of participants are shown in Table 1 and highlight
that participants were more often middle-aged women or older, who had resided in the U.K. for at least
six years and were originally from the Indian sub-continent or Arabic-speaking nations. Unsurprisingly,
given the demographic profile, the majority of participants were regular attendees of the pharmacy,
receiving repeat medication for the management of long-term conditions.
Table 1. Demographic data of participants.
Characteristic Frequency
Gender
Male 58 (38%)
Female 92 (61%)
Age group
18–25 7 (5%)
26–40 40 (27%)
41–60 37 (25%)
Over 60 64 (42%)
Length of time in the U.K.
Less than 1 years 8 (5%)
1–5 years 22 (15%)
6–10 years 29 (19%)
More than 10 years 89 (59%)
Native language
Arabic 51 (34%)
Bengali 31 (21%)
Gujarati 14 (9%)
Hindi 14 (9%)
Polish 9 (6%)
Punjabi (Gurmukhi) 18 (12%)
Somali 4 (3%)
Tamil 10 (7%)
Not all patients answered all questioned, hence, percentages may not always sum to 100%.
Participants were asked to rate their abilities in written and spoken English. Findings for both
were broadly similar; just under a quarter (23%, n = 35) thought that their understanding of written
and spoken English was very good or good, with a slightly higher percentage stating it was poor or
very poor (30%, n = 46 for spoken, and 38%, n = 57 for written). The remaining participants rated their
ability as fair.
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The questionnaire revealed that participants often did not read the English information on the
dispensing labels and when they did, they frequently did not understand what was written on them,
which resulted in participants often asking for help from someone to explain the information. In this
sample, 77% of patients (n = 117) required support from an interpreter “always”, “most of the time”,
or “sometimes”. However, the majority still believed they took the medicines as intended (Table 2).
Where participants said they did not take the medicine as specified, uncertainty was the main reason
(35%, n = 53).
Table 2. Participants’ responses on understanding of English dispensing labels and actions taken.
“Always” or “Most
of the Time” “Sometimes”
“Rarely” or
“Never”
Do you read the information on the labels of your medicines
(example shown below)? 36% (n = 55) 37% (n = 56) 26% (n = 40)
How often do you understand this information? * 38% (n = 57) 41% (n = 62) 21% (n = 31)
Does someone else help you to understand this information? 39% (n = 59) 38% (n = 58) 23% (n = 34)
How often would you say that you take the right amount of your
medicines (for example, the right number of puffs from the inhaler,
the right volume of liquid from a bottle or the right number of
tablets) and at the right time, as specified by the label? †
58% (n = 88) 27% (n = 41) 11% (n = 16)
* One patient did not answer; † Four patients were “not sure” and two patients did not answer.
3.2. Follow-Up Questionnaire Data
The second questionnaire was completed by 130 of the original 151 participants. Reasons for
non-participation in the follow-up questionnaire or whether this questionnaire was completed in the
pharmacy or over the phone were not recorded. Of those 130 participants, 98% (n = 128) read the
translated information on the dispensing labels. Almost all of these found this information easy to
understand all or most of the time (89%, n = 114). Consequently, only 25% (n = 32) of the participants
at the follow-up (n = 128) required someone to help them to understand the information on the label
in their preferred language. Those who stated needing help (n = 32) were asked who had helped
them with this information, and they indicated that these were most often “pharmacy staff” (n = 19),
followed by “friends or family” (n = 14), and “others” (n = 3), with participants being able to select
more than one option in this part of the questionnaire. They were also asked a series of questions
about the impact the translated dispensing labels had on aspects of their adherence. Details of these
responses are included in Table 3.
Table 3. Participants’ responses with regards to the impact on aspects of self-reported adherence when
receiving labels in their preferred language.
“Yes” “No” “NotSure”
Do you think the translated information helped you to take your medicines
at the right time as specified on the label?
82%
(n = 105)
8%
(n = 10)
10%
(n = 13)
Do you think the translated information helped you to use the right
amount of medicine, as specified on the medication label (for example, the
right number of puffs from the inhaler, the right volume of liquid from a
bottle, or the right number of tablets)?
83%
(n = 106)
6%
(n = 7)
12%
(n = 15)
After reading the translated information, did you notice you were taking
your medicines in a way other than that specified on the medication label? *
62%
(n = 46)
30%
(n = 22)
8%
(n = 6)
* Subset of patients who only received “repeated” medicines, not “new”, “both”, or “not sure”, n = 74.
Findings were overwhelmingly positive, with over 80% believing that the translated information
helped them to take the correct dose at the right time. Additionally, of those participants who
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were receiving repeat medication, more than half identified that they had been taking previous
medicines inappropriately.
Most participants (79%, n = 101) wished to receive translated labels on a regular basis in the
future, and consequently would influence their choice of pharmacy, with the majority of participants
(66%, n = 84) stating that they would always or mostly visit a pharmacy offering such a service.
A complete data summary can be found in the Supplementary Materials.
4. Discussion
These exploratory results show that people with limited English proficiency struggle to
understand the English information provided on dispensing labels. Indeed, a substantial proportion
of participants rarely or never read the labels. Participants acknowledged that they frequently sought
explanation from others. In this study, this was provided primarily by a bilingual staff member.
While this would address some of the communication barriers they experienced, concerns exist
around the lack of trained interpreters available in healthcare settings, and the associated risk of
miscommunication [13,21]. After receiving the bilingual dispensing labels, participants reported a
marked increase in reading the dispensing labels with an associated reduction in further explanation
required by someone. It was also noteworthy to find that 62% of people had identified instances
where they were taking their medication inappropriately. These findings support other work that
shows this population is at high risk of poor health outcomes and susceptible to adverse medicine
effects [7,10–12].
In the U.K., the use of standard pharmacy dispensing labels containing information in English
allows community pharmacies to meet legal requirements, but when these are received by patients
with limited English, they seem unable to meet their fundamental purpose. With a substantial and
growing population in the U.K. having English as an additional language [7,8], and similar trends
elsewhere, there appears to be a need for similar services.
Limitations
This study was small-scale and exploratory in nature, and therefore does have a number of
limitations that need to be acknowledged. Firstly, the results are limited by the nature of self-reporting
for understanding medical instructions. This would be an important element for future studies to
address, either with qualitative studies on how patients were utilizing this type of service or how
it impacted medication-taking behaviour or with adherence-focused quantitative studies. Secondly,
we did not objectively assess participant level of English proficiency at recruitment. This needs to be
taken into consideration as approximately a quarter of study participants appeared not to have limited
English proficiency. Lastly, although a quality assurance mechanism was in place to determine the
appropriateness of translated labels, no formal validation was conducted. Cultural differences and
how they may impact understanding and interpreting medicines instructions were not explored as part
of this work. In addition, the participation numbers were relatively small, affecting generalizability of
the results.
This study has shown that patients value the provision of bilingual labels and highlights that
medicines may be being taken inappropriately if only English labels are provided. Pharmacies could
consider adopting the practice of providing bilingual labels where need exists. Further research would
be needed to look at cultural differences and health beliefs that could affect how medicine information
is interpreted and understood within each of the languages.
Supplementary Materials: The following are available online at http://www.mdpi.com/2226-4787/7/1/
32/s1, Two study questionnaires and complete data summary which shows responses to all questions in
both questionnaires.
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